PDF herunterladen
CC BY-NC-ND 4.0 · Pharmacopsychiatry 2024; 57(06): 296-303
DOI: 10.1055/a-2374-2386
Original Paper

Twenty-Three Years of Declining Lithium Use: Analysis of a Pharmacoepidemiological Dataset from German-Speaking Countries

Waldemar Greil    ‡
1   Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Germany
2   Psychiatric Private Hospital, Sanatorium Kilchberg, Zurich, Switzerland
,
Mateo de Bardeci   ‡
2   Psychiatric Private Hospital, Sanatorium Kilchberg, Zurich, Switzerland
3   Department of Psychiatry, Psychotherapy and Psychosomatics, Hospital of Psychiatry, University of Zurich, Zurich, Switzerland
,
Nadja Nievergelt
2   Psychiatric Private Hospital, Sanatorium Kilchberg, Zurich, Switzerland
,
Sermin Toto
4   Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Hannover, Germany
,
Renate Grohmann
1   Department of Psychiatry and Psychotherapy, LMU University Hospital, LMU Munich, Germany
,
Johanna Seifert
4   Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Hannover, Germany
,
Georgios Schoretsanitis
3   Department of Psychiatry, Psychotherapy and Psychosomatics, Hospital of Psychiatry, University of Zurich, Zurich, Switzerland
5   The Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, New York, USA
6   Department of Psychiatry at the Donald and Barbara Zucker School of Medicine at Northwell/Hofstra, Hempstead, NY, USA
› Institutsangaben
› Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Introduction Pharmacoepidemiological data suggest that lithium prescriptions for bipolar disorder are gradually decreasing, with less attention having been paid to other indications.

Methods We examined lithium prescriptions between 1994 and 2017 in data provided by the Drug Safety in Psychiatry Program AMSP, including psychiatric hospitals in Germany, Austria and Switzerland. We compared lithium use for different diagnoses before and after 2001 and in three periods (T1: 1994–2001, T2: 2002–2009, and T3: 2010–2017).

Results In a total of 158,384 adult inpatients (54% female, mean age 47.4±17.0 years), we observed a statistically significant decrease in lithium prescriptions between 1994–2000 and 2001–2017 in patients with schizophrenia spectrum disorder from 7.7% to 5.1% and in patients with affective disorders from 16.8% to 9.6%. Decreases in use were also observed for diagnostic subgroups: schizoaffective disorder (ICD-10 F25: 27.8% to 17.4%), bipolar disorder (F31: 41.3% to 31%), depressive episode (F32: 8.1% to 3.4%), recurrent depression (F33: 17.9% to 7.5%, all: p<0.001) and emotionally unstable (borderline) personality disorder (6.3% to 3.9%, p=0.01). The results in T1 vs. T2 vs. T3 were for F25: 26.7% vs. 18.2% vs. 16.2%, F32: 7.7% vs. 4.2% vs. 2.7%, F33: 17.2% vs. 8.6% vs. 6.6% and for F31: 40.8% vs. 31.7% vs 30.0%, i. e. there was no further decrease for lithium use in bipolar disorder after 2002. Lithium’s main psychotropic co-medications were quetiapine (21.1%), lorazepam (20.6%), and olanzapine (15.2%).

Discussion In inpatients, the use of lithium has decreased in patients with bipolar disorder and also with various other psychiatric diagnoses.

Keywords

lithium - pharmacoepidemiology - bipolar disorders - polypharmacy - psychopharmacology

‡ equal contribution: Waldemar Greil, Mateo de Bardeci


Supplementary Material



Publikationsverlauf

Eingereicht: 13. März 2024

Angenommen nach Revision: 26. Juni 2024

Artikel online veröffentlicht:
22. August 2024

© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 Yatham LN, Kennedy SH, Parikh SV. et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder. Bipolar Disord 2018; 20: 97-170
    CrossrefPubMedGoogle Scholar
  • 2 Ercis M, Ozerdem A, Singh B. When and how to use lithium augmentation for treating major depressive disorder. J Clin Psychiatry 2023; 84: 23ac14813
    CrossrefPubMedGoogle Scholar
  • 3 Leucht S, Helfer B, Dold M. et al. Lithium for schizophrenia. Cochrane Database Syst Rev 2015; 2015: CD003834
    PubMedGoogle Scholar
  • 4 Antolin-Concha D, Lahteenvuo M, Vattulainen P. et al. Suicide mortality and use of psychotropic drugs in patients hospitalized due to bipolar disorder: A Finnish nationwide cohort study. J Affect Disord 2020; 277: 885-892
    CrossrefPubMedGoogle Scholar
  • 5 Lewitzka U, Severus E, Bauer R. et al. The suicide prevention effect of lithium: More than 20 years of evidence-a narrative review. Int J Bipolar Disord 2015; 3: 32
    CrossrefPubMedGoogle Scholar
  • 6 Queissner R, Lenger M, Birner A. et al. The association between anti-inflammatory effects of long-term lithium treatment and illness course in Bipolar Disorder. J Affect Disord 2020; 281: 228-234
    CrossrefPubMedGoogle Scholar
  • 7 Forlenza OV, Diniz BS, Radanovic M. et al. Disease-modifying properties of long-term lithium treatment for amnestic mild cognitive impairment: Randomised controlled trial. Br J Psychiatry 2011; 198: 351-356
    CrossrefPubMedGoogle Scholar
  • 8 Rhee TG, Olfson M, Nierenberg AA. et al. 20-Year Trends in the pharmacologic treatment of bipolar disorder by psychiatrists in outpatient care settings. Am J Psychiatry 2020; 177: 706-715
    CrossrefPubMedGoogle Scholar
  • 9 Kessing LV, Vradi E, Andersen PK. Nationwide and population-based prescription patterns in bipolar disorder. Bipolar Disord 2016; 18: 174-182
    CrossrefPubMedGoogle Scholar
  • 10 Mandal S, Mamidipalli SS, Mukherjee B. et al. Perspectives, attitude, and practice of lithium prescription among psychiatrists in India. Indian J Psychiatry 2019; 61: 451-456
    CrossrefPubMedGoogle Scholar
  • 11 Parabiaghi A, Barbato A, Risso P. et al. Lithium use from 2000 to 2010 in Italy: A population-based study. Pharmacopsychiatry 2015; 48: 89-94
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 12 Poranen J, Koistinaho A, Tanskanen A. et al. Twenty-year medication use trends in first-episode bipolar disorder. Acta Psychiatr Scand 2022; 146: 583-593
    CrossrefPubMedGoogle Scholar
  • 13 Shafiq S, Ronksley PE, Scory TD. et al. Ten-year trends in lithium prescribing in Alberta, Canada. Can J Psychiatry 2023; 69: 13–20 DOI: 10.1177/07067437231176905.
    CrossrefPubMedGoogle Scholar
  • 14 Bridler R, Haberle A, Muller ST. et al. Psychopharmacological treatment of 2195 in-patients with borderline personality disorder: A comparison with other psychiatric disorders. Eur Neuropsychopharmacol 2015; 25: 763-772
    CrossrefPubMedGoogle Scholar
  • 15 Glocker C, Grohmann R, Burkhardt G. et al. Antipsychotic drug-induced neutropenia: Results from the AMSP drug surveillance program between 1993 and 2016. J Neural Transm (Vienna) 2023; 130: 153-163
    CrossrefPubMedGoogle Scholar
  • 16 Seifert J, Maier HB, Fuhrmann F. et al. Pharmacological treatment of major depressive disorder according to severity in psychiatric inpatients: Results from the AMSP pharmacovigilance program from 2001-2017. J Neural Transm (Vienna) 2022; 129: 925-944
    CrossrefPubMedGoogle Scholar
  • 17 Lyall LM, Penades N, Smith DJ. Changes in prescribing for bipolar disorder between 2009 and 2016: National-level data linkage study in Scotland. Br J Psychiatry 2019; 215: 415-421
    CrossrefPubMedGoogle Scholar
  • 18 Lin CH, Chan HY, Chen CC. et al. Prescribing changes for bipolar patients discharged from two public psychiatric hospitals in Taiwan, 2006-2019. J Affect Disord 2022; 318: 386-392
    CrossrefPubMedGoogle Scholar
  • 19 Greil W, de Bardeci M, Muller-Oerlinghausen B. et al. Controversies regarding lithium-associated weight gain: Case-control study of real-world drug safety data. Int J Bipolar Disord 2023; 11: 34
    CrossrefPubMedGoogle Scholar
  • 20 Malhi GS, Bell E, Jadidi M. et al. Countering the declining use of lithium therapy: A call to arms. Int J Bipolar Disord 2023; 11: 30
    CrossrefPubMedGoogle Scholar
  • 21 Puranen A, Koponen M, Lahteenvuo M. et al. Real-world effectiveness of mood stabilizer use in schizophrenia. Acta Psychiatr Scand 2023; 147: 257-266
    CrossrefPubMedGoogle Scholar
  • 22 Baethge C, Gruschka P, Berghofer A. et al. Prophylaxis of schizoaffective disorder with lithium or carbamazepine: Outcome after long-term follow-up. J Affect Disord 2004; 79: 43-50
    CrossrefPubMedGoogle Scholar
  • 23 Martin-Blanco A, Ancochea A, Soler J. et al. Changes over the last 15 years in the psychopharmacological management of persons with borderline personality disorder. Acta Psychiatr Scand 2017; 136: 323-331
    CrossrefPubMedGoogle Scholar
  • 24 Greil W, Ludwig-Mayerhofer W, Erazo N. et al. Comparative efficacy of lithium and amitriptyline in the maintenance treatment of recurrent unipolar depression: A randomised study. J Affect Disord 1996; 40: 179-190
    CrossrefPubMedGoogle Scholar
  • 25 Coppen A, Abou-Saleh MT. Lithium in the prophylaxis of unipolar depression: A review. J R Soc Med 1983; 76: 297-301
    CrossrefPubMedGoogle Scholar
  • 26 Barnes TR, Drake R, Paton C. et al. Evidence-based guidelines for the pharmacological treatment of schizophrenia: Updated recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2020; 34: 3-78
    CrossrefPubMedGoogle Scholar
  • 27 Greil W, Ludwig-Mayerhofer W, Erazo N. et al. Lithium vs carbamazepine in the maintenance treatment of schizoaffective disorder: A randomised study. Eur Arch Psychiatry Clin Neurosci 1997; 247: 42-50
    CrossrefPubMedGoogle Scholar
  • 28 Kriner P, Severus E, Korbmacher J. et al. Lithium prescription trends in psychiatric inpatient care 2014 to 2021: Data from a Bavarian drug surveillance project. Int J Bipolar Disord 2023; 11: 40
    CrossrefPubMedGoogle Scholar
  • 29 Lohse MJ, Müller-Oerlinhausen B. Psychopharmaka. In: Schwabe U, Paffrath D, Ludwig WD, Klauber J eds, Arzneiverordnungs-Report 2018. Berlin: Springer; 2018: 733-762
    Google Scholar
  • 30 Tokumitsu K, Yasui-Furukori N, Adachi N. et al. Predictors of psychiatric hospitalization among outpatients with bipolar disorder in the real-world clinical setting. Front Psychiatry 2023; 14: 1078045
    CrossrefPubMedGoogle Scholar